

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/271601999>

# Interrogating alkyl and arylalkylpolyamino (bis)urea and (bis)thiourea isosteres as potent antimalarial chemotypes...

Article in *Bioorganic & Medicinal Chemistry* · January 2015

DOI: 10.1016/j.bmc.2015.01.036

CITATIONS

3

READS

110

12 authors, including:



**Janette Reader**

University of Pretoria

9 PUBLICATIONS 43 CITATIONS

SEE PROFILE



**Timothy J Egan**

University of Cape Town

162 PUBLICATIONS 4,531 CITATIONS

SEE PROFILE



**Patrick M. Woster**

Medical University of South Carolina

156 PUBLICATIONS 4,888 CITATIONS

SEE PROFILE



**Lyn-Marie Birkholtz**

University of Pretoria

61 PUBLICATIONS 461 CITATIONS

SEE PROFILE

Some of the authors of this publication are also working on these related projects:



Simple derivatisation of the old coccidiostat decoquinatone to provide new 'drug-like' derivatives suitable for treatment of malaria and other parasitic diseases, and TB [View project](#)



Contents lists available at ScienceDirect

## Bioorganic &amp; Medicinal Chemistry

journal homepage: [www.elsevier.com/locate/bmc](http://www.elsevier.com/locate/bmc)

## Interrogating alkyl and arylalkylpolyamino (bis)urea and (bis)thiourea isosteres as potent antimalarial chemotypes against multiple lifecycle forms of *Plasmodium falciparum* parasites

Bianca K. Verlinden<sup>a</sup>, Marna de Beer<sup>a</sup>, Boobalan Pachaiyappan<sup>b</sup>, Ethan Besaans<sup>a</sup>, Warren A. Andayi<sup>a</sup>, Janette Reader<sup>a</sup>, Jandeli Niemand<sup>a</sup>, Riette van Biljon<sup>a</sup>, Kiplin Guy<sup>c</sup>, Timothy Egan<sup>d</sup>, Patrick M. Woster<sup>b</sup>, Lyn-Marie Birkholtz<sup>a,\*</sup>

<sup>a</sup> Department of Biochemistry, Faculty of Natural and Agricultural Sciences, Centre for Sustainable Malaria Control, University of Pretoria, Private Bag x20, Pretoria 0028, South Africa

<sup>b</sup> Department of Drug Discovery and Biomedical Sciences, Medical University of South Carolina, Charleston, SC 29425, USA

<sup>c</sup> Department of Chemical Biology and Therapeutics, St Jude Children's Research Hospital, Memphis, TN, USA

<sup>d</sup> Department of Chemistry, University of Cape Town, Medical School, Observatory 7925, South Africa

## ARTICLE INFO

## Article history:

Received 31 October 2014

Revised 20 January 2015

Accepted 21 January 2015

Available online xxx

## Keywords:

Malaria

*Plasmodium*

Polyamine analogue

Antimalarial drugs

(Bis)urea

(Bis)thiourea

## ABSTRACT

A new series of potent aryl/alkylated (bis)urea- and (bis)thiourea polyamine analogues were synthesized and evaluated *in vitro* for their antiparasmodial activity. Altering the carbon backbone and terminal substituents increased the potency of analogues in the compound library 3-fold, with the most active compounds, **15** and **16**, showing half-maximal inhibitory concentrations (IC<sub>50</sub> values) of 28 and 30 nM, respectively, against various *Plasmodium falciparum* parasite strains without any cross-resistance. *In vitro* evaluation of the cytotoxicity of these analogues revealed marked selectivity towards targeting malaria parasites compared to mammalian HepG2 cells (>5000-fold lower IC<sub>50</sub> against the parasite). Preliminary biological evaluation of the polyamine analogue antiparasmodial phenotype revealed that (bis)urea compounds target parasite asexual proliferation, whereas (bis)thiourea compounds of the same series have the unique ability to block transmissible gametocyte forms of the parasite, indicating pluripharacology against proliferative and non-proliferative forms of the parasite. In this manuscript, we describe these results and postulate a refined structure–activity relationship (SAR) model for antiparasmodial polyamine analogues. The terminally aryl/alkylated (bis)urea- and (bis)thiourea–polyamine analogues featuring a 3-5-3 or 3-6-3 carbon backbone represent a structurally novel and distinct class of potential antiparasmodials with activities in the low nanomolar range, and high selectivity against various lifecycle forms of *P. falciparum* parasites.

© 2015 Elsevier Ltd. All rights reserved.

## 1. Introduction

Malaria remains a deadly parasitic disease transmitted to humans by the female *Anopheles* mosquito in the tropical and sub-tropical parts of the world and still causes approximately 600,000 deaths each year, mostly of African children. At present, the primary component of parasite control remains the use of

antimalarial drugs; however, these have to remain effective against a background of continuous development of drug resistant parasite strains. As a result, global efforts are focused on the development of novel antimalarial chemotypes with unique mechanisms of action compared to currently used antimalarial drugs. The antimalarial drug pipeline is currently populated by, for instance, imidazolopiperazines,<sup>1</sup> spiroindolones,<sup>2</sup> synthetic peroxides,<sup>3</sup> dihydroorotate dehydrogenase inhibitors<sup>4</sup> and 3,5-diaryl-2-aminopyridines<sup>5</sup> ([www.mmv.org](http://www.mmv.org)). However, several other chemotypes are effective antiproliferative agents against both cancer and parasitic diseases, and we have previously explored some of these as starting points to assess their efficacy against malaria parasites. Although cancer and parasitic diseases have different etiologies, they share pathophysiological features including

**Abbreviations:** BW-1, 1,15-[N-(2-phenyl)benzyl]amino-4,12-diazapentadecane; DFMO,  $\alpha$ -difluoromethylornithine; FIC, fractional inhibitory concentrations; MDL 27695, 1,15-(N-benzyl)amino-4,12-diazapentadecane; RI, resistance indices; SAR, structure–activity relationship; SI, selectivity index.

\* Corresponding author. Tel.: +27 12 420 2479; fax: +27 12 362 5302.

E-mail address: [lbirkholtz@up.ac.za](mailto:lbirkholtz@up.ac.za) (L.-M. Birkholtz).

<http://dx.doi.org/10.1016/j.bmc.2015.01.036>

0968-0896/© 2015 Elsevier Ltd. All rights reserved.

uncontrolled, rapid proliferation; enhanced metabolic activities; some signal transduction pathways and immune evasion strategies.

Biogenic amines and polyamines (the naturally occurring spermidine and spermine, and their precursor putrescine) are well recognized for their pleiotropic biological activities during cell growth and development, making them essential constituents of highly proliferative cell types including cancerous cells and parasites.<sup>6</sup> While the  $pK_a$  values of the amine groups within the polyamine chain vary, these groups are all essentially protonated, and are positively charged at physiological pH.<sup>7</sup> Polyamines are therefore able to electrostatically interact with RNA, DNA, dTNPs, proteins, and other anionic substances, thereby modulating their functions. The polyamines therefore play essential roles in many of the following processes: cell growth, proliferation, differentiation, synthesis of nucleic acids and proteins, cell adhesion, signaling processes and in the repair of the extracellular matrix.

Inhibition of polyamine biosynthesis is well recognized for its therapeutic efficacy against parasitic diseases including *Trypanosoma brucei gambiense* infections (West African sleeping sickness).<sup>8</sup> Moreover, analogues of the naturally occurring polyamines are structurally similar to the natural polyamines but act as either antimetabolites or polyamine mimetics, thereby resulting in the non-functional replacement of the natural polyamines from their specific effector sites.<sup>9,10</sup> These chemotypes were originally studied for their antiproliferative properties against various forms of cancer,<sup>11</sup> but terminally (bis)aryl/alkylated polyamine analogues such as compounds **1–5** (Fig. 1) and (bis)biguanides such as verlindamycin (compound **6**; Fig. 1) have previously been reported as highly effective antiparasitic agents against various parasites.<sup>8,12,13</sup> In particular, compound **4** was found to be curative for the microsporidia *Encephalitozoan cuniculi* in a murine model.<sup>8</sup> Compound **1** demonstrated impressive antileishmanial activity, eliminating *Leishmania donovani* amastigotes from mouse macrophages at 1  $\mu$ M concentrations.<sup>14</sup> This analogue was also an effective antitrypanosomal agent, inhibiting the *In vitro* growth of various drug-sensitive and -resistant strains of *T. brucei* parasites.<sup>15</sup> Compound **5** had an  $IC_{50}$  of 110 nM against the intraerythrocytic *P. falciparum* drug-sensitive 3D7 strain and an  $IC_{50}$  of 120 nM against the *P. falciparum* Dd2 drug-resistant strain and was as effective as pyrimethamine at reducing parasitemia and extending life span in a murine model of *Plasmodium yoelii* (unpublished observations). Compound **1** also presented remarkable antimalarial activity and was curative of disease in a *P. berghei* malaria model.<sup>16</sup> Additionally, mice treated with compound **1** combined with a polyamine biosynthesis inhibitor were resistant to *Plasmodium berghei* re-infections.<sup>16</sup> This finding demonstrated the prospective value of the polyamine pathway as a drug target in Plasmodia.<sup>17</sup>

As part of our continued search for structurally novel antimalarials, potent terminally substituted aryl/alkylated (bis)urea and (bis)thiourea polyamine analogues based on the lead compound verlindamycin (**6**) were synthesized and evaluated for their antimalarial properties.<sup>18</sup> These compounds contained 3-3-3, 3-4-3, 3-6-3 or 3-7-3 carbon backbone architecture, combined with a variety of terminal substituents. The majority of these compounds possessed  $IC_{50}$  values below 500 nM against intraerythrocytic *P. falciparum* parasites. The leading compound in this series, (bis)urea **7** ( $IC_{50}$  = 88 nM) contained a 3-6-3 carbon backbone architecture and terminal phenyl substitutions. Importantly, these polyamine analogues represent a chemotype of highly selective antiplasmodial agents (>7000-fold *In vitro* selectivity compared to mammalian HepG2 cells) and produce a significant irreversible, cytotoxic response in the parasite.<sup>18</sup>

In an effort to complete the characterization and interrogate potential structure–activity relationships for this chemotype, we report here additional isosteres based on the structure of

compound **6** that feature a 3-5-3 carbon backbone architecture (**8–16**). (Bis)urea- and (bis)thiourea analogues with the 3-5-3 backbone architecture have not yet been reported or evaluated in any antiparasitic assay systems. These compounds were evaluated here for their ability to inhibit the *In vitro* proliferation of both drug-sensitive and drug-resistant strains of *P. falciparum* parasites. With this data, we now have a structurally complete polyamine library, spanning the backbone pharmacophore from the 3-3-3 nonspermine scaffold to an extended 3-7-3 scaffold, all with various terminal substitutions. This library has facilitated the development of a preliminary structure activity relationship model for these novel antiplasmodial agents.

## 2. Results and discussion

### 2.1. Chemistry


Polyamine analogues exemplify a class of compounds that are structurally distinct from any existing antimalarial drug or new chemotype under investigation. To enable comparative analysis of the complete chemotype based on variant polyamine backbones, compounds **8–16** were designed as a novel series with 3-5-3 polyamine backbones. These compounds were synthesized using adaptations of our previously reported synthesis, as shown in Scheme 1.<sup>18,19</sup> A reaction of  $N^4,N^{10}$ -(bis)-[(*tert*-butyloxy)carbonyl]-1,14-aminotridecane **17** with the appropriate isothiocyanate or isocyanate gave the corresponding protected (bis)thiourea analogues **18–21**, or the protected (bis)urea analogues **22–26**, respectively. Removal of the N-Boc protection groups (1.0 M HCl in EtOAc) provided the desired (bis)thiourea polyamines **8–11**, and the (bis)urea polyamines **12–16**.

### 2.2. Biological activity

#### 2.2.1. *In vitro* antiplasmodial activity against asexual parasites

To interrogate the antiplasmodial activity of the 3-5-3 polyamine backbone series, compounds **8–16** were evaluated for their antiplasmodial activities against drug-sensitive and -resistant strains of intraerythrocytic *P. falciparum* parasites *In vitro*. In the *In vitro* assay, compounds with  $IC_{50}$  values  $\leq$  100 nM were considered potentially active, while compounds with  $IC_{50}$  values between 100 and 900 nM were considered active. Thus **9–16** were identified as antiplasmodial agents against the 3D7 strain of intraerythrocytic *P. falciparum* parasites, with activities between 28 and 793 nM (Table 1). The two most potent 3-5-3 compounds, (bis)ureas **15** and **16**, had  $IC_{50}$  values of 28 and 30 nM, respectively. Compounds **8** and **12** had moderate activities of 249 and 246 nM, respectively, while compound **13** was found to be the least active against the 3D7 strain of *P. falciparum*, with an  $IC_{50}$  of 793 nM.

Parallel cross-reactivity screening against drug resistant strains of intraerythrocytic *P. falciparum* parasites indicated resistance indices (RI, ratio of the  $IC_{50}$  values of resistant to sensitive strain) from 0.17 to 1.2, compared to the calculated chloroquine value of 7.8 (Table 1). This strongly suggests that these compounds would not share the same resistance mechanism as chloroquine or that their activity is independent of such resistance mechanisms. The two most active 3-5-3 carbon backbone compounds against the 3D7 strain, compounds **15** and **16**, did not show any cross-resistance and both were highly active against both the antifolate-resistant HB3 strain (compound **15**  $IC_{50}$  = 40 nM; compound **16**  $IC_{50}$  = 56 nM, Table 1) and the chloroquine-resistant W2 strains of intraerythrocytic *P. falciparum* (compound **15**  $IC_{50}$  = 18 nM; compound **16**  $IC_{50}$  = 36 nM, Table 1). In addition, compound **10** proved to be equipotent with **16**, with an  $IC_{50}$  = 56 nM against the *P. falciparum* HB3 strain. In the chloroquine-resistant W2 strain of intraerythrocytic *P. falciparum* parasites, all compounds except




**Figure 1.** Structures of (bis)alkylpolyamines (compounds 1–5), verlindamycin (compound 6) and 1,14-bis-(phenylurea)-tetradecane (compound 7).

compound **13** had  $IC_{50}$  values below 50 nM, and compounds **14** and **15** showed the greatest activity (**14**  $IC_{50}$  = 20 nM; **15**  $IC_{50}$  = 18 nM). Interestingly, this strain also seemed more sensitive overall to polyamine perturbation.

The antiproliferative effect of the polyamine analogues may, in addition to the polyamine functionality, also be due to the effect on

other metabolic activities of the parasite as both (bis)urea and bis(thiourea) derivatives have been reported to be  $\beta$ -hematin inhibitors, similar to the action of chloroquine.<sup>20–22</sup> To further investigate the activity of the series on the chloroquine resistant W2 parasites, compound **10** (the most active thiourea), **16** (one of the leading urea compounds) and **13** (a urea and the least active



Scheme 1.

**Table 1**  
In vitro antiplasmodial activity of 3-5-3 carbon backbone aryl/alkylated polyamine analogues against various strains of intraerythrocytic *P. falciparum* parasites

Compd			<i>P. falciparum</i> IC <sub>50</sub> (nM)			
	R	X	3D7 <sup>a</sup>	W2 <sup>b</sup>	HB3 <sup>c</sup>	RI <sup>d</sup>
<b>8</b>	Benzyl	S	249 ± 30	42 ± 6	178 ± 2	0.17
<b>9</b>	Diphenylmethyl	S	68 ± 13	35 ± 3	75 ± 9	0.51
<b>10</b>	Diphenylethyl	S	40 ± 9	47 ± 1	56 ± 3	1.18
<b>11</b>	Diphenylpropyl	S	76 ± 24	41 ± 3	62 ± 7	0.54
<b>12</b>	Phenyl	O	246 ± 34	49 ± 13	177 ± 4	0.20
<b>13</b>	Benzyl	O	793 ± 78	171 ± 25	593 ± 20	0.22
<b>14</b>	Diphenylmethyl	O	47 ± 7	20 ± 3	65 ± 2	0.43
<b>15</b>	Diphenylethyl	O	28 ± 4	18 ± 3	40 ± 3	0.64
<b>16</b>	Diphenylpropyl	O	30 ± 5	36 ± 7	56 ± 7	1.20
CQ	Chloroquine	–	9 ± 0.04	70 ± 1	–	7.78


All data points are the average of 3 or more determinations ± SE.

<sup>a</sup> *P. falciparum* 3D7, chloroquine-sensitive, (n = 9).

<sup>b</sup> *P. falciparum* W2, chloroquine-resistant (n = 4).

<sup>c</sup> *P. falciparum* HB3, antifolate-resistant (n = 3).

<sup>d</sup> Resistance index (RI) defined as the ratio of the IC<sub>50</sub> values of the resistant to sensitive strains, W2/3D7.



**Figure 2.** Investigating similarities to chloroquine action. (A) Summary of the activity of a selection of the 3-5-3 series to drug sensitive (3D7) and chloroquine (CQ) resistant (W2) *P. falciparum* parasites. (B) Dose–response curves (μM) of CQ (circle), compound **10** (square) and compound **16** (triangle) with the NP-40 mediated β-hematin formation assay. Absorbance was measured at 405 nm. In each instance, data are of three independent biological repeats performed in triplicate, ±SE.

compound) were screened for their ability to inhibit hemozoin (β-hematin) formation (Fig. 2). Due to the catabolism of erythrocyte hemoglobin, the intraerythrocytic *P. falciparum* parasite is

exposed to cytotoxic oxidative stress caused by the free heme formation.<sup>23</sup> Aggregating the heme into hemozoin crystals circumvents this and interference with this process has been ascribed as

the mode of action of quinoline type antimalarials. All compounds tested had showed significantly poor abilities to inhibit  $\beta$ -hematin formation compared to chloroquine at an  $IC_{50}$  of  $10.1 \pm 1.2 \mu M$  (Fig. 2). Even though compound **10** was able to inhibit  $\beta$ -hematin formation with an  $IC_{50}$  of  $16.7 \pm 0.07 \mu M$ , this was still significantly less ( $P = 0.0054$ ,  $n = 3$ ) than that of CQ. More dramatically, compound **16**, with a RI of 1.2 only showed activity at  $>400 \mu M$  and compound **13** showed no activity even at 1 mM, indicating that  $\beta$ -hematin inhibition is not the primary mechanism of action for these two compounds.

### 2.2.2. In vitro antiplasmodial evaluation: cytotoxicity evaluation

All polyamine analogues from the 3-5-3 series was found to be highly selective towards intraerythrocytic *P. falciparum* parasites, as concurrent counter-screening for In vitro cytotoxicity against mammalian HepG2 cells determined the selectivity index (SI, activity against mammalian cells to that against *P. falciparum*; Table 2). With the exception of compounds **9** (SI = 659 fold) and **11** (SI = 666 fold), the majority of the compounds showed  $>1000$ -fold selectivity toward the parasite. Moreover, compounds **15** and **16** are not only the most active against the *P. falciparum* 3D7 parasite, but also highly selective for the parasite, with SI values of 3375 and 5090, respectively. The polyamine parent molecule from which the 3-5-3 series was derived has previously been shown to produce a low level of general cytotoxicity, and the observed antitumor effect is primarily through re-expression of aberrantly silenced tumor suppressor genes. As such, this series is not inherently cytotoxic to non-cancerous mammalian cells when administered alone.<sup>18</sup> Interestingly, the enhanced sensitivity of *P. falciparum* parasites compared to mammalian cells has also been observed with phenylacetamido-polyamines having nM activity against the parasite with low general cytotoxicity.<sup>24,25</sup>

### 2.2.3. In vitro antiplasmodial activity: stage-specificity and kinetics

A major goal of antimalarial discovery programs is to define the cidal nature of compounds, in addition to descriptors of stage-specificity and kinetics of killing. Ideally, new antimalarials should be fast acting on all stages of the *P. falciparum* parasite's life cycle to fulfill target candidate profile (TCP) 1 criteria, or alternatively, be relatively slow acting but still affecting all lifecycle stages to be used in combination treatments, fulfilling TCP 2.<sup>26</sup> Treatment of intraerythrocytic *P. falciparum* 3D7 parasites with the 3-5-3 series of polyamine analogues resulted in a non-progressive pyknotic phenotype with a apparently dead or dying morphology

corresponding to the stage of parasite affected as early trophozoites (Fig. 3A). Early ring stage parasites were not affected by treatment with these compounds. The phenotype corresponds moreover to a similar phenotype observed with polyamine biosynthesis inhibitors (such as difluoromethylornithine, Fig. 3A), indicating a stage-specific preference of action of these polyamine analogues correlating to the requirement of polyamines for biological function in the parasites.<sup>18,27</sup>


Quantification of this phenotype confirmed that the parasites treated with compounds **15** and **16** could not progress beyond early trophozoite stages (Fig. 3B) and this effect was observed within the first 24 h of drug treatment. Due to the nature of the flow cytometric measurement (detection of DNA content through SYBR Green I fluorescence), it was also clear that these analogues enforce their inhibitory activity through preventing DNA synthesis. The dramatic halt in schizogony distinctly correlated to a cessation of nuclear division with parasites containing  $\sim 88\%$  rings/trophozoites (1 N) with only  $\sim 10\%$  2 N and  $\sim 2\%$   $>2$  N schizonts at 96 h after treatment (compound **16**, Fig. 3B). These results are similar to previous reports where the utter requirement of *P. falciparum* parasites of polyamines for nuclear division and cell cycle progression was indicated.<sup>18</sup> Again, the data supports the requirement of these metabolites for DNA synthesis and nuclear division in the schizont stages.<sup>27</sup>

With the activity of the lead compounds from this series clearly established on early trophozoite stage parasites, we subsequently evaluated the kinetics thereof. Parasite proliferation ceased entirely within the first 24 h of drug treatment for both compounds **15** and **16**, continuously for two lifecycles (96 h) at  $1 \times IC_{90}$  (Fig. 3C). To fully investigate the long-term effects of exposure to compound **16** (as example) including the ability of parasites to overcome drug pressure if only dormant after treatment, parasite proliferation was monitored for 18, 24, 36 and 48 h after a single 12 h pulse with the compound ( $1 \times IC_{90}$ ; Fig. 3D). An irreversible decrease in intraerythrocytic *P. falciparum* 3D7 parasite viability ( $>40\%$ , as measured by parasite proliferation over 36 h) was seen after this single 12 h pulse with no outgrowth observed even at  $10 \times IC_{90}$ , confirming the rapid and cidal nature of this perturbation. Previous polyamine analogues (e.g., compound **7**) were also characterized as targeting early trophozoite forms of the parasite with rapid action (within the first 24 h of drug pressure),<sup>18</sup> indicating that these compounds have a relatively fast and cidal mode of action.<sup>28</sup>

Antimalarial drug discovery programs currently focus not only on novel descriptors of chemotherapies against asexual, blood stage parasites but also, to support malaria elimination endeavors,

**Table 2**


In vitro antiplasmodial activity of 3-5-3 carbon backbone aryl/alkylated polyamine analogues against various strains of intraerythrocytic *P. falciparum* parasites

Compd			<i>P. falciparum</i> 3D7 $IC_{50}$ (nM)	HepG2 $GI_{50}$ ( $\mu M$ )	SI <sup>e</sup>
	R	X			
<b>8</b>	Benzyl	S	$249 \pm 30$	100% viability <sup>*</sup>	$>5000$
<b>9</b>	Diphenylmethyl	S	$68 \pm 13$	$44.8 \pm 0.8$	659
<b>10</b>	Diphenylethyl	S	$40 \pm 9$	$52.20 \pm 7$	1305
<b>11</b>	Diphenylpropyl	S	$76 \pm 24$	$50.6 \pm 2$	666
<b>12</b>	Phenyl	O	$246 \pm 34$	100% viability <sup>*</sup>	$>5000$
<b>13</b>	Benzyl	O	$793 \pm 78$	$1947.33 \pm 43$	2456
<b>14</b>	Diphenylmethyl	O	$47 \pm 7$	$240.3 \pm 11$	5113
<b>15</b>	Diphenylethyl	O	$28 \pm 4$	$94.5 \pm 9$	3375
<b>16</b>	Diphenylpropyl	O	$30 \pm 5$	$152.7 \pm 8$	5090
CQ	Chloroquine	—	$9 \pm 0.04$	$43.09 \pm 2$	4788

All data points are the average of 3 or more determinations  $\pm$  SE.

<sup>e</sup> Selectivity index (SI) was determined as the compound  $GI_{50}$  mammalian cell/ $IC_{50}$  *P. falciparum*.

<sup>\*</sup> No inhibition of HepG2 viability at  $5000 \times IC_{50}$  (3D7 value).




**Figure 3.** Stage-specificity and kinetics evaluation of antiplasmodial action. (A) Morphological monitoring (Giemsa stained microscopy) of intraerythrocytic *P. falciparum* parasites treated with lead compound **16** ( $IC_{90}$ ) over a single 48 h life cycle compared to a polyamine biosynthesis inhibitor, difluoromethylornithine (DFMO) or to untreated (DMSO) control parasites. (B) Flow cytometric analysis of nuclear content of intraerythrocytic *P. falciparum* parasites treated with compound **15** and **16** ( $1 \times IC_{90}$ ) using SYBR Green-I in the FITC channel. Parasite population (%) illustrates rings and early trophozoite stage parasites based on their 1 N nuclear content. After nuclear division the trophozoites contain 2 N and the multi-nucleated schizonts contain  $>2$  N. Nuclear content was measured with flow cytometric analysis. (C) Intraerythrocytic *P. falciparum* parasites were treated with compounds **15** and **16** ( $1 \times IC_{90}$ ) for 96 h and parasitemia monitored by flow cytometry compared to untreated, DMSO control parasites. (D) Dose-dependent cidal action of compound **16** was indicated as follows: ring stage parasites were treated with  $1 \times$  (diamond) and  $10 \times$  (square)  $IC_{90}$  of compound **16** and chloroquine (triangle, control) for 12 h, washed and allowed to proliferate for 36 h. Proliferation was measured at different time points with the SYBR Green-I fluorescence.

need to additionally identify compounds with action against the sexual, gametocyte forms of the parasites to be used as malaria transmission blocking drugs.<sup>26,29</sup> For the first time, we also show that polyamine analogues not only target the asexual intraerythrocytic development of *P. falciparum* parasites but have the ability to also affect the viability of sexual stages of *P. falciparum* parasites. Compounds **8–16** were analyzed for their gametocytocidal activity at  $5 \mu\text{M}$  (48 h) against early ( $>90\%$  stage II/III) and late ( $>90\%$  stage IV/V) gametocytes of *P. falciparum* using a luciferase reporter assay<sup>30</sup> (Fig. 4). Thioureated compounds (except for **8**) were particularly interesting as they had a preference for late-stage gametocytes, with **9** and **11** fully inhibitory at the concentration tested. This finding is significant given the current focus of malaria drug discovery efforts on identification of potential gametocytocidal compounds, with killing of mature gametocytes seen as highly desirable for transmission blocking compounds.<sup>26</sup> The urea-based compounds all had relatively poor activity against both early- and late-stage gametocytes but overall showed a preference towards early gametocytes, correlating with their significant activity against the asexual forms of the parasite. Nonetheless, the polyamine chemotype does not have any chemical signatures corresponding to any other compound series that have been described before for gametocytocidal activity (e.g.,<sup>31,32</sup>) and this therefore extends their potential applications as antiplasmodials useful as either chemotherapeutics or transmission blocking drugs.

### 2.3. Structure–activity relationship analysis

The data presented above, together with a number of series previously tested,<sup>18</sup> allowed for completion of the polyamine backbone to a full series (3-3-3, 3-4-3, 3-5-3, 3-6-3 and 3-7-3) tested for activity against *P. falciparum* parasites. The antiplasmodial chemotype is considered complete as previous have shown that extending the central carbon beyond 7 carbons results in greater toxicity in a malaria mouse model.<sup>36</sup> The analogues containing a 3-3-3, 3-4-3, 3-6-3 or 3-7-3 carbon backbone architecture, combined with a variety of terminal substituents (compounds **7**, **27–57**, Fig. 5,<sup>18</sup>), as well as the new (bis)urea- and (bis)thiourea analogues of **7** with 3-5-3 carbon backbone architecture (**8–16**), were considered.

By applying a primary filter of 100 nM for activity, the majority of the 3-5-3 series (with the exception of compounds **8**, **12**, **13**) passed these selection criteria. However, among previously reported (bis)urea compounds (Fig. 5), only the 3-6-3 phenyl substituted analogue (compound **7**) had an  $IC_{50}$  value below 100 nM, but compound **7** was as selective towards the parasite as compounds **8**, **10**, **14**, **15**, **16**, **28**, **29** all with SI  $>1000$ , indicative of little to no hepatotoxicity at least *In vitro*. Regrettably, compound **1** previously showed hepatotoxicity in preclinical trials;<sup>33</sup> this prompted preliminary predictions of ADME and druggability properties of the compounds tested *in silico*. Overall, the compounds show moderate solubility and permeability with lead



**Figure 4.** Gametocytocidal activity of the 3-5-3 series against *P. falciparum* parasites. NF54-luc reporter strains of the parasite were used to induce gametocytogenesis and activity (% inhibition of luciferase readout) of the compounds assayed at 5  $\mu$ M after 48 h exposure. Both early gametocytes (>90% stage II/II gametocytes) as well as mature gametocytes (>90% stage IV/V gametocytes) were assayed independently. Data are of three independent biological repeats performed in triplicate,  $\pm$ SE.

compounds **15**, **16** (3-5-3 series) and **7** (3-6-3 series) displaying QED values of 0.21, suggesting possible druggability.

Based upon the compiled data for the chemotype (Fig. 5), the structure–activity relationship (SAR) correlations for symmetrically aryl/alkylated (bis)urea- and (bis)thiourea-polyamine analogues could be refined. Further objective chemi-informatic analysis of SAR was employed to define the contributions of the carbon backbone and terminal substituents to antimalarial activity (Fig. 6). Activity cliff analyses<sup>34,35</sup> were created analyzing either the pairwise structural similarity and associated activities based on the carbon backbone (Fig. 6) or on the terminal substituents, in each case with an 80% structural similarity threshold.

A distinct correlation was observed between antiplasmodial activity and length of the central carbon spacers. Our data suggests that, in the (bis)urea series, a central carbon spacer of 5 or 6 carbons is optimal for antiplasmodial activity *in vitro* (Fig. 6). Backbone clustering clearly confirmed that a 3-5-3 backbone shows preferred activity below the 100 nM filter. Additionally, all (except for one 3-4-3 backbone pair, compounds **36–34**) the additional compounds below a 500 nM activity filter are from either the 3-7-3 (63%) or 3-6-3 (21%) series. This corroborates previous work, which showed that extending the central carbon beyond 7 carbons results in greater toxicity in the malaria mouse model.<sup>36</sup> The spacing of these nitrogens<sup>37</sup> and the  $pK_a$  of the terminal nitrogens<sup>38</sup> have a significant effect on normal polyamine biological activity. The nitrogens in the polyamines spermidine and spermine are fully protonated at physiological pH, and it is thus generally assumed that they interact with 3 or 4 anionic sites at a biological target.<sup>39</sup> However, the  $pK_a$  of the terminal nitrogen equivalent does not appear to be as critical, particularly in polyamine analogues. Compounds such as **1** have terminal secondary nitrogens with

$pK_a$  values near 10 that are protonated at physiological pH. However, since substituted ureas and thioureas do not have acid–base characteristics at physiological pH, it would appear that the ability to hydrogen bond at the terminal urea or thiourea moiety is sufficient for retaining activity. Terminal guanidines or biguanides produce enhanced antiproliferative effects as these moieties would result in an even larger charge perturbation than the natural polyamines.<sup>40</sup> Substituted guanidines and biguanides, possessing  $pK_a$  values of 13.53<sup>41</sup> and 13.03<sup>42</sup> respectively, are more basic than the terminal nitrogens of polyamines with  $pK_a$  values approximating 10<sup>43</sup> and are therefore likely to interfere with polyamine metabolism.<sup>11</sup>

Within the 3-5-3 backbone, structural changes from (bis)urea to (bis)thiourea were associated with relative loss in activity to asexual forms of *P. falciparum* parasites (Fig. 6). Additionally, the (bis)urea analogues in the 3-5-3 series (compounds **14**, **15**, **16**) proved to be more selective towards the parasite compared to mammalian cells than their thiourea isosteres (compounds **9**, **10**, **11**). However, the preference for (bis)urea analogues in this series does not hold true when activity is evaluated against the non-replicating gametocyte forms of the parasite, where clear preference is seen towards (bis)thiourea analogues. This could indicate pluripharacology for this chemotype as either antimalarial chemotherapies or transmission blocking drugs. Further exploitation of the potential transmission blocking activity of this series is underway.

However, the activities described above are completely dependent on symmetrical terminal nitrogen substituents; size, flexibility and electronic character appear to affect antiplasmodial activity, with clear preference towards diphenylaryl constituents compared to monoarylalkylation. Here, the diphenylethyl substituent appears



Compound	Terminal	Internal	Backbone	3D7	W2	HB3	RI	HepG2 uM	SI (HepG2/Pf)	Solubility	Permeability	HIA
15	diphenylethyl	O	3-5-3	28 ± 4	18 ± 3	40 ± 3	0.64	94.5 ± 9	3375	-0.738		2
16	diphenylpropyl	O	3-5-3	30 ± 5	36 ± 7	56 ± 7	1.2	152.7 ± 8	5090	-0.32		2
10	diphenylethyl	S	3-5-3	40 ± 9	47 ± 1	56 ± 3	1.18	52.20 ± 7	1305	-2.308		3
14	diphenylmethyl	O	3-5-3	47 ± 7	20 ± 3	65 ± 2	0.43	240.3 ± 11	5113	-1.635		2
9	diphenylmethyl	S	3-5-3	68 ± 13	35 ± 3	75 ± 9	0.51	44.8 ± 0.8	659	-3.205		3
11	diphenylpropyl	S	3-5-3	76 ± 24	41 ± 3	62 ± 7	0.54	50.6 ± 2	666	-1.89		3
7	phenyl	O	3-6-3	88 ± 7	26 ± 1		0.3	619.3 ± 25.8	7038	31.3	188.16	0
27	diphenylethyl	O	3-7-3	100 ± 3	140 ± 5		1.4	33.8 ± 3.24	338	43.6	10.88	2
28	benzyl	S	3-6-3	106 ± 11	198 ± 15		1.9	>200	>1500	59.2	372.9	0
29	diphenylmethyl	O	3-7-3	131 ± 2	221 ± 7		1.7	> 200	> 1500	38	35.71	2
30	diphenylpropyl	O	3-7-3	144 ± 31	162.6 ± 3.2	200 ± 9	1.13	23.92 ± 0.4	166	31.4	8.1	3
31	diphenylmethyl	S	3-6-3	211 ± 7	256 ± 4		1.2	> 200	> 500	38.5	2.04	3
12	phenyl	O	3-5-3	246 ± 34	49 ± 13	177 ± 4	0.2	100% viability	> 5000	-1.241		0
8	benzyl	S	3-5-3	249 ± 30	42 ± 6	178 ± 2	0.17	100% viability	> 5000	-2.288		0
32	diphenylpropyl	S	3-7-3	253 ± 3	147 ± 4	256 ± 17	0.58	24.52 ± 1.4	97	2.5	0.08	3
6	Biguanide	NH	3-7-3	298 ± 27		224 ± 80				0.514		3
33	diphenylpropyl	S	3-6-3	310 ± 8						-1.695		3
34	diphenylethyl	S	3-4-3	329 ± 9	200 ± 17	170 ± 32	0.61	18.92 ± 1.3	58	10.4	1.41	2
35	benzyl	O	3-6-3	339 ± 70						-0.816		0
36	benzyl	S	3-4-3	355 ± 90	66 ± 14		0.19	> 200	> 500	33.7		0
37	diphenylethyl	S	3-7-3	405 ± 8	183.1 ± 2.9		0.45	24.67 ± 0.3	61	-1.99		3
38	diphenylethyl	O	3-4-3	408 ± 5						-0.861		2
39	propyl	S	3-6-3	425 ± 40						-1.785		0
40	diphenylmethyl	S	3-4-3	433 ± 9		317 ± 37				-3.281		2
41	diphenylethyl	S	3-6-3	436 ± 11						-2.161		3
42	diphenylpropyl	S	3-4-3	528 ± 9		1031 ± 83				-2.06		3
43	diphenylmethyl	S	3-7-3	641 ± 8		138 ± 17				-2.981		3
44	diphenylpropyl	O	3-3-3	653 ± 44						-0.528		2
45	diphenylpropyl	O	3-4-3	657 ± 90		517 ± 43				-0.491		2
46	diphenylmethyl	O	3-4-3	691 ± 9						-1.712		2
13	benzyl	O	3-5-3	793 ± 78	171 ± 25	593 ± 20	0.22	1947.33 ± 43	2456	-0.718		0
47	phenyl	S	3-6-3	846 ± 25						-2.941		0
48	diphenylmethyl	S	3-3-3	1081 ± 15		766 ± 24				-3.228		2
49	diphenylethyl	S	3-3-3	1316 ± 10		715 ± 76				-2.421		2
50	ethyl	S	3-6-3	1353 ± 60						-1.215		0
51	diphenylpropyl	S	3-3-3	1434 ± 22		1641 ± 104				-2.098		3
52	benzyl	O	3-4-3	3475 ± 600		> 1000				-0.604		0
53	propyl	O	3-6-3	14084 ± 600						-0.215		0
54	ethyl	O	3-6-3	> 15000						0.355		0
55	Amidine	NH	3-4-3	80000 ± 75000		14200 ± 4900				0.888		1
56	Amidine	NH	3-3-3	147000 ± 23000		109500 ± 13000				1.297		1
57	Amidine	NH	3-7-3			70300 ± 25000				0.047		0

IC <sub>50</sub> / nM	RI	Cytotoxicity / μM	SI	Solubility (μM)	Predictive solubility	Permeability nm/s	HIA
< 50	0*0.5	> 50	> 500	> 50	Good	> 100	0 (Good)
50-100	0.5-1	40*50	200*500	10*50	Optimal	10*100	1 (Moderate)
100*1000	1*1.5	30*40	100*200	1*10	Very low/ too soluble	< 10	2 (Poor)
1000*5000	1.5*2	< 30	< 100		Poor		3 (Very poor)
5000*15000							

**Figure 5.** Evaluation of the (bis)urea- and (bis)thiourea polyamine chemotype. Data from this study (3-5-3 series, compounds 8–16) as well as previous studies<sup>18</sup> (compounds 7, 27–57) were compiled and compared for their antiplasmodial activity (IC<sub>50</sub> values, various strains), selectivity (HepG2 and SI), physicochemical properties (solubility, permeability and HIA). Data were ranked according to 3D7 potency (IC<sub>50</sub> values) with a color gradient scale indicating more potent activity / desirable features in darker squares. Solubility was either obtained physically at pH 7.4 or predicted with Discovery Studio. Permeability was indicated with a PAMPA assay. HIA predictors were obtained through Discovery Studio analysis.

to be optimal (among analogues examined to date), possibly due to favorable hydrophobic contacts with the biological target. In (bis)urea analogues with the 3-5-3 backbone, the phenyl and benzyl substituted compounds **12** and **13** exhibited a dramatic decrease in activity, exhibiting IC<sub>50</sub> values of 246 and 793 nM, respectively (pairs **12–13** and **8–13**, Fig. 6). Conversely, compounds with diphenylaryl substitutions such as compounds **14–16** retained the antiplasmodial activity, with the diphenylethyl substituted analogue **15** being the most potent compound IC<sub>50</sub> = 28 nM (3D7) and 18 nM (W2). In all but 3 examples in Figure 5, compounds featuring the diphenylethyl substituent are more potent than the corresponding diphenylmethyl or diphenylpropyl homologues, possibly due to a combination of steric and electronic effects including pi stacking.


In the (bis)thiourea series, a different SAR emerged. The 3-6-3 (bis)benzyl analogue **28** (IC<sub>50</sub> 106 nM) and the 3-6-3 (bis)diphenylmethyl analogue **31** (IC<sub>50</sub> 211 nM) had activity below 250 nM. In the corresponding 3-5-3 series, the (bis)benzyl analogue **8** (IC<sub>50</sub> 249 nM) was significantly less potent than the corresponding 3-6-3 homologue **28**, while the diphenylaryl compounds **9–11** all had IC<sub>50</sub> values below 80 nM. The diphenylethyl compound **10** was the most potent among these three (IC<sub>50</sub> 40 nM). Compounds with simple alkyl substituents such as compounds **53** and **54** were

inactive. Analogues that featured a diphenylalkyl terminal substitution were not significantly more potent than **7**.


In summary, the preliminary SAR for symmetrically substituted (bis)urea- and (bis)thiourea-polyamines against intraerythrocytic *P. falciparum* parasites could be delineated based on the mono- or diarylalkyl constituency as follows (Fig. 7): In all cases, the best linker is an alkylation, preferably ethyl and X = O. In the (bis)monoaryalkyl compounds, there is a preference for phenyl terminal substituents and n<sub>1</sub> = 4 (3-6-3), with n<sub>1</sub> = 3 (3-5-3) significantly reducing activity for this series. These compounds are most like the lead compound **1**, and as such these data extend the SAR from previous studies.<sup>12,36</sup> In the more potent (bis)diarylalkyl series, preference exist for diphenylethyl and where n<sub>1</sub> = 3 (3-5-3) compared to n<sub>1</sub> = 4 (3-6-3), the reduction of the central carbon chain by 1 carbon increases antiplasmodial activity by as much as 10-fold compared to the (bis)monoaryalkyl compounds.

### 3. Conclusions

The terminally aryl/alkylated (bis)urea- and (bis)thiourea-polyamine analogues of the 3-5-3 and 3-6-3 carbon backbone represent a structurally novel and distinct class of potential antiplasmodials with activities in the low nanomolar range and



**Figure 6.** Structure activity landscape analysis for the symmetrically substituted (bis)urea- and (bis)thiourea polyamines. Pairwise activity to structural feature analysis was performed with Activity Cliff Analysis (Osiris DataWarrior V 3.12.1) on the complete series from Figure 5 at a stringency of 80% similarly in structural features. Cluster analysis based on backbone structural features. In all cases, two structurally similar isosteres were compared and a single bar acts as identifier of such correlations based on the respective activities of the two isosteres as indicated on the two axes (decreasing potency from crosspoint). Activity values are based on the In vitro IC<sub>50</sub> values in nM (asexual *P. falciparum* parasites 3D7). Isostere pairs are identified numerically based on compound numbers in Figure 5 for example, 15–16 with activity 1–activity 2 descriptors.



**Figure 7.** Antiplasmodial structure activity relationship model for symmetrically substituted (bis)urea- and (bis)thiourea polyamines.

high selectivity against intraerythrocytic *P. falciparum* parasites. Further mechanistic studies and in vivo activity determinations are currently underway.

## 4. Materials and methods

### 4.1. Chemistry

#### 4.1.1. Reagents

All reagents and dry solvents were purchased from Aldrich Chemical Co. (Milwaukee, WI), Sigma Chemical Co. (St. Louis, MO) Fisher Scientific (Chicago, IL) or VWR Scientific (Atlanta, GA) and were used without further purification except where noted below. Triethylamine was distilled from potassium hydroxide and stored in a nitrogen atmosphere. Dry methanol, ethyl acetate, tetrahydrofuran, dimethyl formamide and hexane were prepared using a Glass Contour Solvent Purification System (Pure Process Technology, LLC, Nashua, NH). Methanol was distilled from magnesium and iodine

under a nitrogen atmosphere and stored over molecular sieves. Routine chromatographic purification on silica gel was performed on a Teledyne Isco CombiFlash Rf200. Preparative scale chromatographic procedures were carried out using E. Merck silica gel 60, 230–440 mesh. Thin layer chromatography was conducted on Merck precoated silica gel 60 F-254. All <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded on a Varian Mercury 400 MHz spectrometer, and all chemical shifts are reported as  $\delta$  values referenced to TMS. In all cases, <sup>1</sup>H NMR, <sup>13</sup>C NMR and mass spectra were consistent with assigned structures. Mass spectra were recorded on a Kratos MS 80 RFA (EI and CI) or Kratos MS 50 TC (FAB) mass spectrometer. *N*<sup>4</sup>,*N*<sup>10</sup>-(Bis)-[*tert*-butyloxy]carbonyl]-1,14-aminotridecane **17** was synthesized from 1,5-diaminopentane as previously described.<sup>19,44</sup> Prior to biological testing, previously unreported target molecules **8–16** were determined to be 95% pure or greater by UPLC chromatography using a Waters Acquity system with a photodiode array (PDA) detector (190–500 nm) fitted with a C18 reversed-phase column.

### 4.2. General procedure for the synthesis of *N*-Boc protected (bis)ureas and (bis)thioureas

#### 4.2.1. 1,13-Bis-[3-[1-(benzyl)thiourea]-4,10-di(*tert*-butyloxy)carbonyl]-4,10-diazatridecane, **18**

A 203 mg (1.361 mmol) portion of benzyl isothiocyanate dissolved in 10 mL of anhydrous dichloromethane was added to 270 mg (0.648 mmol) of **17** in 20 mL of anhydrous dichloromethane in a drop wise fashion. The reaction mixture was allowed to stir at room temperature for 24 h. During this time, the formation of product was monitored by TLC (75% ethyl acetate in hexane). After the completion of the reaction, the solvent was removed in vacuo and the crude product was purified on silica gel eluted with 75% ethyl acetate in hexane to afford 315 mg of pure **18** as a white

solid (68%).  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ):  $\delta$  7.32–7.25 (m, 10H), 4.57 (s, 4H), 3.90 (m, 4H), 4.10 (m, 4H), 1.71 (m, 4H), 1.56–1.47 (m, 4H), 1.40 (s, 18H), 1.23–1.20 (m, 2H).  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ ):  $\delta$  181.01, 156.70, 136.97, 128.68, 127.64, 79.98, 47.51, 47.01, 43.25, 41.14, 28.38, 27.09, 24.18.  $M^+$  = 714.4,  $[\text{M}+1]^+$  = 715.3.

#### 4.2.2. 1,13-Bis-{3-[1-(1',1'-diphenylmethyl)thiourea]}-4,10-di(tert-butylloxycarbonyl)-4,10-diazatridecane, 19

Compound **19** was prepared from **17** (218 mg, 0.523 mmol) and 2,2-diphenylmethylisothiocyanate (236 mg, 1.047 mmol) using the general procedure described above. Yield 348 mg (71%).  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ):  $\delta$  7.43–7.26 (m, 20H), 6.50 (s, 2H), 3.53 (m, 4H), 3.075 (m, 8H), 1.67 (m, 4H), 1.51–1.48 (m, 4H), 1.38 (s, 18H), 1.24–1.18 (m, 2H).  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ ):  $\delta$  180.07, 156.64, 140.25, 128.75, 127.84, 127.58, 79.89, 61.42, 47, 42.93, 41.31, 28.32, 26.95, 24.17;  $M^+$  = 866.46,  $[\text{M}+1]^+$  = 867.2.

#### 4.2.3. 1,13-Bis-{3-[1-(2',2'-diphenylethyl)thiourea]}-4,10-di(tert-butylloxycarbonyl)-4,10-diazatridecane, 20

Compound **20** was prepared from **17** (200 mg, 0.48 mmol) and 2,2-diphenylethylisothiocyanate (230 mg, 0.96 mmol) using the general procedure described above. Yield 292 mg (68%).  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ):  $\delta$  7.33–7.21 (m, 20H), 5.9 (s, 2H), 4.14–4.05 (m, 4H), 3.55 (m, 4H), 3.26 (m, 4H), 3.12 (t, 4H), 1.71 (m, 4H), 1.54 (m, 4H), 1.29 (s, 18H), 1.27 (t, 4H,  $J$  = 6.8 Hz);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ ):  $\delta$  181.22, 156.78, 141.55, 128.78, 128.08, 126.94, 80.08, 49.85, 47, 43.29, 40.99, 28.41, 26.96, 24.22.  $M^+$  = 894.49,  $[\text{M}+1]^+$  = 895.3.

#### 4.2.4. 1,13-Bis-{3-[1-(3',3'-diphenylpropyl)thiourea]}-4,10-di(tert-butylloxycarbonyl)-4,10-diazatridecane, 21

Compound **21** was prepared from **17** (200 mg, 0.48 mmol) and 3,3-diphenylpropylisothiocyanate (255 mg, 1.008 mmol) using the general procedure described above. Yield 328 mg (74%).  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ):  $\delta$  7.31–7.17 (m, 20H), 4.05 (t, 2H,  $J$  = 8.32 Hz), 3.55 (m, 4H), 3.3–3.25 (m, 8H), 3.12 (m, 4H), 2.41–2.36 (m, 4H), 1.71 (m, 4H), 1.56–1.53 (m, 4H), 1.43 (s, 18H), 1.29–1.26 (m, 2H);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ ):  $\delta$  171.19, 156.77, 143.95, 128.63, 127.75, 126.46, 80.01, 48.69, 46.99, 43.22, 40.94, 34.48, 31.59, 27.05, 24.22, 22.66.  $M^+$  = 922.52,  $[\text{M}+1]^+$  = 923.4.

#### 4.2.5. 1,13-Bis-{3-[1-(phenyl)urea]}-4,10-di(tert-butylloxycarbonyl)-4,10-diazatridecane, 22

Compound **22** was prepared from **17** (268 mg, 0.643 mmol) and phenylisocyanate (153 mg, 1.287 mmol) using the general procedure described above. Yield 282 mg (67%).  $^1\text{H}$  NMR ( $\text{CD}_3\text{OD}$ ):  $\delta$  7.34–7.32 (m, 8H), 7.23 (t, 2H,  $J$  = 7.6 Hz), 6.99 (t, 2H,  $J$  = 7.24 Hz), 3.19–3.10 (m, 12H), 1.65 (m, 4H), 1.44 (m, 22H), 1.19 (m, 2H).  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ ):  $\delta$  156.49, 156.16, 139.27, 128.96, 122.76, 119.82, 79.80, 46, 44, 36.38, 28.45, 24.09.  $M^+$  = 654.41,  $[\text{M}+1]^+$  = 655.2.

#### 4.2.6. 1,13-Bis-{3-[1-(benzyl)urea]}-4,10-di(tert-butylloxycarbonyl)-4,10-diazatridecane, 23

Compound **23** was prepared from **17** (282 mg, 0.677 mmol) and benzylisocyanate (189 mg, 1.422 mmol) using the general procedure described above. Yield 324 mg (70%).  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ):  $\delta$  7.28 (m, 10H), 4.32 (s, 4H), 3.21–3.11 (m, 12H), 1.61 (m, 4H), 1.52–1.47 (m, 22H), 1.24–1.20 (m, 2H).  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ ):  $\delta$  158.59, 156.27, 139.53, 128.49, 127.37, 127.08, 79.56, 46.99, 44.32, 43.6, 36.8, 28.44, 24.11.  $M^+$  = 682.44,  $[\text{M}+1]^+$  = 683.3.

#### 4.2.7. 1,13-Bis-{3-[1-(1',1'-diphenylmethyl)urea]}-4,10-di(tert-butylloxycarbonyl)-4,10-diazatridecane, 24

Compound **24** was prepared from **17** (230 mg, 0.552 mmol) and 2,2-diphenylmethylisothiocyanate (243 mg, 1.159 mmol) using the general procedure described above. Yield 332 mg (72%).  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ):  $\delta$  7.40–7.10 (m, 20H), 5.99 (d, 2H), 3.3–2.9

(m, 12H), 1.54 (m, 4H), 1.43 (m, 22H), 1.2 (m, 2H);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ ):  $\delta$  157.78, 156.25, 142.62, 128.51, 127.36, 127.14, 58.13, 47.01, 45.09, 43.67, 36.73, 28.46, 25.30, 24.15.  $M^+$  = 834.5,  $[\text{M}+1]^+$  = 835.3.

#### 4.2.8. 1,13-Bis-{3-[1-(2',2'-diphenylethyl)urea]}-4,10-di(tert-butylloxycarbonyl)-4,10-diazatridecane 25

Compound **25** was prepared from **17** (200 mg, 0.48 mmol) and 2,2-diphenylethylisocyanate (225 mg, 1.008 mmol) using the general procedure described above. Yield 290 mg (70%).  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ):  $\delta$  7.31–7.19 (m, 20H), 4.19 (t, 2H,  $J$  = 7.8 Hz), 3.81 (t, 2H,  $J$  = 7.1 Hz), 3.22 (m, 4H), 3.10 (m, 8H), 1.61 (m, 4H), 1.51 (m, 4H), 1.43 (s, 18H), 1.23 (m, 2H);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ ):  $\delta$  158.16, 142.22, 128.63, 128.16, 126.66, 79.61, 51.21, 46.91, 44.98, 44.46, 36.5, 28.45, 28.24. Exact mass = 862.54,  $[\text{M}+1]^+$  = 863.3.

#### 4.2.9. 1,13-Bis-{3-[1-(3',3'-diphenylpropyl)urea]}-4,10-di(tert-butylloxycarbonyl)-4,10-diazatridecane 26

Compound **26** was prepared from **17** (217 mg, 0.521 mmol) and 3,3-diphenylpropylisocyanate (260 mg, 1.094 mmol) using the general procedure described above. Yield 348 mg (75%).  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ):  $\delta$  7.30–7.16 (m, 20H), 3.99 (t, 2H,  $J$  = 7.5 Hz), 3.30–3.26 (m, 4H), 3.15–3.10 (m, 12H), 2.30–2.24 (m, 4H), 1.67 (m, 4H), 1.54–1.51 (m, 4H), 1.46 (s, 18H), 1.25–1.22 (m, 2H);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ ):  $\delta$  158.48, 156.5, 144.41, 128.54, 127.81, 126.29, 79.59, 48.8, 46.94, 39.21, 36.01, 28.47.  $M^+$  = 890.57,  $[\text{M}+1]^+$  = 891.3.

### 4.3. General procedure for the deprotection of the N-Boc protecting group

#### 4.3.1. 1,13-Bis-{3-[1-(benzyl)thiourea]}-4,10-diazatridecane dihydrochloride, 8

A stirred solution of 0.1 g (0.140 mmol) of the (bis)-N-Boc protected (bis)thiourea derivative **18** in 25 mL of 1.0 M HCl in ethyl acetate was allowed to stir overnight at room temperature, and the formation of the product was monitored by TLC. The product precipitated as a crystalline solid during the course of the reaction. After the completion of the reaction, the solvent was removed under reduced pressure followed by the addition of fresh ethyl acetate, and the mixture was stirred for 15 min and decanted. The solid thus obtained was dried in vacuo as above to afford the final product **8** in 85% yield (69.9 mg).  $^1\text{H}$  NMR ( $\text{CD}_3\text{OD}$ ):  $\delta$  7.4–7.26 (m, 10H), 4.34 (s, 4H), 3.31 (t, 4H,  $J$  = 6.2 Hz), 3.01–2.98 (m, 4H), 2.91 (m, 4H), 1.88–1.85 (m, 4H), 1.72–1.68 (m, 4H), 1.48–1.46 (m, 2H);  $^{13}\text{C}$  NMR ( $\text{CD}_3\text{OD}$ ):  $\delta$  128.21, 127.09, 126.99, 47.06, 44.51, 40.20, 26.39, 25.31, 25.28, 23.15.

#### 4.3.2. 1,13-Bis-{3-[1-(1',1'-diphenylmethyl)thiourea]}-4,10-diazatridecane dihydrochloride, 9

Compound **9** was synthesized from **19** (100 mg, 0.115 mmol) as per the procedure described above in 85% yield (72.5 mg).  $^1\text{H}$  NMR ( $\text{CD}_3\text{OD}$ ):  $\delta$  7.45–7.27 (m, 20H), 6.67 (s, 2H), 3.78 (t, 4H,  $J$  = 5.76 Hz), 3.00–2.94 (m, 8H), 1.72–1.69 (m, 4H), 1.55 (br, 4H), 1.48–1.46 (m, 2H);  $^{13}\text{C}$  NMR ( $\text{CD}_3\text{OD}$ ):  $\delta$  141.72, 132.48, 129.62, 128.23, 127.27, 127.07, 61.38, 47.04, 44.50, 40.12, 26.43, 25.83, 25.22, 23.10.  $M^+$  (2HCl) = 666.35; calculated = 667.2.

#### 4.3.3. 1,13-Bis-{3-[1-(2',2'-diphenylethyl)thiourea]}-4,10-diazatridecane dihydrochloride, 10

Compound **10** was synthesized from **20** (100 mg, 0.112 mmol) as per the procedure described above in 90% yield (77 mg).  $^1\text{H}$  NMR ( $\text{CD}_3\text{OD}$ ):  $\delta$  7.32–7.22 (m, 20H), 4.45 (s, 2H), 4.13 (t, 4H,  $J$  = 7.08 Hz), 3.67 (m, 4H), 3.04–2.97 (m, 8H), 1.92–1.89 (m, 4H), 1.80–1.77 (m, 4H), 1.56–1.53 (m, 2H);  $^{13}\text{C}$  NMR ( $\text{CD}_3\text{OD}$ ):  $\delta$  142.22, 128.29, 127.86, 126.39, 50.22, 47.09, 44.04, 39.87, 26.41, 25.31, 23.17.  $M^+$  (2HCl) = 694.39; calculated = 695.3.

#### 4.3.4. 1,13-Bis-{3-[1-(3,3'-diphenylpropyl)thiourea]}-4,10-diazatridecane dihydrochloride, 11

Compound **11** was synthesized from **21** (100 mg, 0.108 mmol) as per the procedure described above in 87% yield (75 mg). <sup>1</sup>H NMR (CD<sub>3</sub>OD): δ 7.30–7.16 (m, 20H), 4.05 (t, 2H, J = 7.6 Hz), 3.70 (br, 4H), 3.41 (br, 4H), 3.04–2.99 (m, 8H), 2.4–2.34 (m, 4H), 1.99–1.92 (m, 4H), 1.8–1.72 (m, 4H), 1.54–1.51 (m, 2H); <sup>13</sup>C NMR (CD<sub>3</sub>OD): δ 144.43, 128.17, 127.50, 125.97, 48.59, 44.48, 40.04, 34.41, 26.46, 25.26, 23.12. M<sup>+</sup> (2HCl) = 722.42; calculated = 723.3.

#### 4.3.5. 1,13-Bis-{3-[1-(phenyl)urea]}-4,10-diazatridecane dihydrochloride, 12

Compound **12** was synthesized from **22** (100 mg, 0.153 mmol) as per the procedure described above in 85% yield (68.5 mg). <sup>1</sup>H NMR (CD<sub>3</sub>OD): δ 7.39 (d, 4H, J = 7.92 Hz), 7.28 (t, 4H, J = 7.6 Hz), 7.02 (t, 2H, 7.28 Hz), 3.36 (t, 4H, J = 6.2), 3.10–3.03 (m, 8H), 1.96–1.91 (m, 4H), 1.83–1.76 (m, 4H), 1.60–1.56 (m, 2H); <sup>13</sup>C NMR (CD<sub>3</sub>OD): δ 157.76, 139.20, 128.51, 122.46, 119.25, 119.12, 47.13, 44.91, 35.83, 26.99, 25.3, 23.06; M<sup>+</sup> (2HCl) = 454.31; calculated = 455.2.

#### 4.3.6. 1,13-Bis-{3-[1-(benzyl)urea]}-4,10-diazatridecane dihydrochloride, 13

Compound **13** was synthesized from **23** (100 mg, 0.146 mmol) as per the procedure described above in 90% yield (73.2 mg). <sup>1</sup>H NMR (CD<sub>3</sub>OD): δ 7.47–7.28 (m, 10H), 4.7 (s, 4H), 3.75 (br, 4H), 3.04–3.01 (m, 8H), 1.99–1.96 (m, 4H), 1.81–1.75 (m, 4H), 1.55 (m, 2H); <sup>13</sup>C NMR (CD<sub>3</sub>OD): δ 160.47, 139.87, 128.48, 128.16, 126.69, 47.09, 44.71, 43.42, 35.72, 27.12, 25.32, 22.99. M<sup>+</sup> (2HCl) = 482.34; calculated = 483.2.

#### 4.3.7. 1,13-Bis-{3-[1-(1,1'-diphenylmethyl)urea]}-4,10-diazatridecane dihydrochloride, 14

Compound **14** was synthesized from **24** (100 mg, 0.12 mmol) as per the procedure described above in 88% yield (74.6 mg). <sup>1</sup>H NMR (CD<sub>3</sub>OD): δ 7.37–7.25 (m, 20H), 5.98 (s, 2H), 3.3 (m, 4H), 2.94 (m, 4H), 2.76 (m, 4H), 1.87 (m, 4H), 1.59 (m, 4H), 1.34 (m, 2H). <sup>13</sup>C NMR (CD<sub>3</sub>OD): δ 159.72, 142.67, 129.63, 128.27, 126.93, 58.07, 47.12, 44.63, 35.52, 27.11, 25.27, 22.94. M<sup>+</sup> (2HCl) = 634.4; calculated = 635.3.

#### 4.3.8. 1,13-Bis-{3-[1-(2,2'-diphenylethyl)urea]}-4,10-diazatridecane dihydrochloride, 15

Compound **15** was synthesized from **25** (100 mg, 0.116 mmol) as per the procedure described above 89% yield (76 mg). <sup>1</sup>H NMR (CD<sub>3</sub>OD): δ 7.33–7.21 (m, 20H), 4.2 (t, 2H, J = 8.0 Hz), 3.81 (d, 4H), 3.23 (t, 4H, 5.8 Hz), 2.98 (t, 4H, J = 7.1 Hz), 2.92 (t, 4H, J = 6.3 Hz), 1.8 (m, 8H), 1.57 (m, 2H); <sup>13</sup>C NMR (CD<sub>3</sub>OD): δ 160.3, 142.54, 128.25, 127.82, 126.29, 51.37, 44.66, 44.33, 35.59, 27.12, 25.43, 23.09. M<sup>+</sup> (2HCl) = 662.43; observed calculated = 663.3.

#### 4.3.9. 1,13-Bis-{3-[1-(3,3'-diphenylpropyl)urea]}-4,10-diazatridecane dihydrochloride, 16

Compound **16** was synthesized from **26** (100 mg, 0.112 mmol) as per the procedure described above 82% yield. <sup>1</sup>H NMR (CD<sub>3</sub>OD): δ 7.3–7.17 (m, 20H), 4.02 (t, 2H, J = 7.8 Hz), 3.27 (t, 4H, J = 6.08 Hz), 3.09 (t, 4H, 7 Hz), 3.02–2.94 (m, 8H), 2.28–2.26 (m, 4H), 1.88–1.85 (m, 4H), 1.76–1.72 (m, 4H), 1.50–1.48 (m, 2H); <sup>13</sup>C NMR (CD<sub>3</sub>OD): δ 160.51, 144.59, 128.16, 127.47, 125.93, 48.48, 47.04, 44.71, 38.52, 35.69, 35.46, 27.15, 25.34, 23.0. M<sup>+</sup> (2HCl) = 690.46; calculated = 691.4.

### 4.4. Biological activity evaluations

#### 4.4.1. In vitro cultivation of intraerythrocytic *P. falciparum* parasites

Intraerythrocytic *P. falciparum* parasites (strains 3D7, W2 and HB3) were cultivated in RPMI-1640 culture medium (25 mM

HEPES pH 7.5, 0.2 mM hypoxanthine, 0.024 mg/mL gentamycin, 5 g/L Albumax II, 23.81 mM sodium bicarbonate, 0.2% D-glucose)<sup>45</sup> in human erythrocytes (O<sup>+</sup>, suspended at 5% hematocrit) under hypoxic conditions (5% O<sub>2</sub>, 5% CO<sub>2</sub>, 90% N<sub>2</sub>) with shaking at 37 °C. Cultures were synchronized to >95% in the ring stage with three consecutive rounds of 5% (w/v) D-Sorbitol treatment.<sup>46</sup>

#### 4.4.2. In vitro assessment of antiplasmodial activity against asexual parasites

Intraerythrocytic *P. falciparum* parasites (3D7, W2 and HB3) were used to assess the In vitro antiplasmodial efficacy of the polyamine analogues using a SYBR Green I-based fluorescence assay as previously described.<sup>18,47</sup> Compounds were dissolved in a non-lethal DMSO concentration (<0.025%), serially diluted in culture medium and added to ring stage intraerythrocytic *P. falciparum* parasites (1% parasitemia, 2% hematocrit), incubated at 37 °C for 96 h in a N<sub>2</sub> atmosphere. Chloroquine disulfate was used as positive drug control (0.5 μM; IC<sub>50</sub> 9 ± 0.04 nM) for complete inhibition of parasite proliferation. Parasite proliferation was normalized to the percentage of untreated control, after subtracting the background fluorescence (chloroquine treated samples). Nonlinear regression curves were generated using GraphPad Prism 5, from which the half-maximal inhibitory concentrations (IC<sub>50</sub>) could be determined.

**4.4.2.1. Kinetics and stage-specificity.** Highly synchronized (>95% ring stage) intraerythrocytic *P. falciparum* parasites (2% parasitemia; 5% hematocrit) were treated with each of the polyamine analogues for 12 h at 1× and 10× IC<sub>90</sub>, respectively. After treatment, the parasites were washed once with RPMI 1640 culture medium, diluted (1:40) before further monitoring proliferation at set times over a total period of 36 h by assessing DNA content with SYBR Green I as described above.<sup>48</sup>

**4.4.2.2. Flow cytometric evaluation.** The effect of the aryl/alkylated polyamine analogues on intraerythrocytic *P. falciparum* parasite DNA replication and nuclear division was determined using flow cytometric analysis as described previously.<sup>18</sup> Parasites (2% parasitemia, 2% hematocrit) were treated in duplicate with 2× IC<sub>90</sub> of the polyamine analogues. Following drug treatment, samples (50 μL) were taken at specific time intervals (24, 48, 72 and 96 h) and nuclear content detected through SYBR Green I fluorescence (FITC channel; excitation wavelength of 488 nm with 502 nm long-band-pass and 530 nm band-pass emission filters) with a BD FACS Aria I flow cytometer, analysing 10<sup>6</sup> cells for each sample. Data was analyzed using FlowJo 7.6.5 and Cyflogic.

**4.4.2.3. β-Hematin inhibition assays.** The parasite rids itself of toxic levels of heme released during the degradation of hemoglobin through the lipid-mediated production of hemozoin. The water-lipid interface can be mimicked In vitro to measure the formation of β-hematin (a synthetic analogue of hemozoin). β-Hematin formation was assayed as described previously using the pyridine-ferrichrome method.<sup>23,49</sup> Briefly, a mixture consisting of NP-40 detergent (305.5 μM) water and DMSO was added to polyamine analogues at various concentrations (0–1 M). The samples were then incubated at 37 °C for 5 h with 25 mM hematin (Fluka; Biochemika) in a 1 M acetate buffer (pH 4.8) with occasional shaking.

#### 4.4.3. Cytotoxicity determinations in mammalian cells

Cytotoxicity against human hepatocellular liver carcinoma cells (HepG2) was determined using the lactate dehydrogenase (LDH) assay as previously described.<sup>18</sup> In brief, HepG2 cells (±200,000 cells) were seeded into 96-well plates and grown for 24 h at 37 °C (5% CO<sub>2</sub>, 90% humidity) in Dulbecco's Modified Eagle's

Medium (DMEM) supplemented with 10% heat inactivated fetal bovine serum and 1% penicillin/streptomycin. Subsequently, the HepG2 cells were treated with various concentrations of the polyamine compounds for 48 h, following which the cells were pelleted at 600 g for 10 min and the LDH activity in the supernatant (10  $\mu$ L) measured by adding 100  $\mu$ L LDH reaction mix (Biovision LDH-Cytotoxicity Assay Kit II). The production of the colored water-soluble tetrazolium salt was measured spectrophotometrically at 450 nm.

#### 4.4.4. Induction of *P. falciparum* gametocytogenesis and maintenance of gametocyte cultures

Gametocytogenesis was induced from asexual *P. falciparum* parasites by a combination of nutrient starvation and a drop in hematocrit. Synchronized asexual parasites cultivated as above at 10% parasitemia were diluted to 0.5% parasitemia (6% hematocrit) into glucose-free medium. Cultures were then maintained under hypoxic conditions without shaking. After 72 h, the hematocrit was dropped to 3% (day 0 of induction). Gametocytogenesis was subsequently monitored microscopically with daily medium (glucose-free) changes. Residual asexual parasites were eliminated by continuous 50 mM *N*-acetyl glucosamine NAG, from day 1–4 in the presence of 0.2% glucose.

#### 4.4.5. In vitro assessment of antiplasmodial activity against sexual gametocytes

Luciferase reporter lines NF54-PfS16-GFP-Luc (early gametocyte marker) and NF54-Mal8p1.16-GFP-Luc (late gametocyte marker) (kind gift from David Fidock, Columbia University, USA)<sup>50</sup> enabled stage-specific descriptors of gametocytocidal activities. Assays were performed as described elsewhere (Reader et al., in press). Drug assays were set up on day 5 and 10 (representing early stage I/II/III and mature stage IV/V gametocytes, respectively). In each instance, assays were set up in triplicate using a 2% gametocytemia, 2% hematocrit culture and 48 h drug pressure (5  $\mu$ M) under hypoxic conditions at 37 °C. Luciferase activity was determined in 20  $\mu$ L parasite lysates by adding 50  $\mu$ L luciferin substrate (Promega Luciferase Assay System) at room temperature and detecting resultant bioluminescence at an integration constant of 10 s with the GloMax<sup>®</sup>-Multi+ Detection System with Instinct<sup>®</sup> Software.

#### 4.4.6. Solubility

Solubility assay was carried out on Biomek FX lab automation workstation (Beckman Coulter, Inc., Fullerton, CA) using mSOL Evolution software (pION Inc., Woburn, MA). The detailed method is described as follows: 10 mL of 10 mM compound stock (in DMSO) was added to 190 mL 1-propanol to make a reference stock plate. 5 mL from this reference stock plate was mixed with 70 mL 1-propanol and 75 mL citrate phosphate buffered saline (isotonic) to make the reference plate, and the UV spectrum (250–500 nm) of the reference plate was read. 6 mL of 10 mM test compound stock was added to 594 mL buffer (at pH 3 or 5 or 7.4) in a 96-well storage plate and mixed. The storage plate was sealed and incubated at room temperature for 18 h. The suspension was then filtered through a 96-well filter plate (pION Inc., Woburn, MA). 75 mL filtrate was mixed with 75 mL 1-propanol to make the sample plate, and the UV spectrum of the sample plate was read. Calculations were carried out by mSOL Evolution software based on the AUC (area under curve) of UV spectrum of the sample plate and the reference plate. All compounds were tested in triplicates.

#### 4.4.7. Permeability

Parallel Artificial Membrane Permeability Assay (PAMPA) was conducted by Biomek FX lab automation workstation (Beckman Coulter, Inc., Fullerton, CA) and PAMPA evolution 96 command

software (pION Inc., Woburn, MA). The detailed method is described as following. 3 mL 10 mM test compound stock in DMSO was mixed with 597 mL of citrate phosphate buffered saline (isotonic) to make diluted test compound. 150 mL of diluted test compound was transferred to a UV plate (pION Inc., Woburn, MA) and the UV spectrum was read as the reference plate. The membrane on pre-loaded PAMPA sandwich (pION Inc., Woburn, MA) was painted with 4 mL GIT lipid (pION Inc., Woburn, MA). The acceptor chamber was then filled with 200 mL ASB (acceptor solution buffer, pION Inc., Woburn, MA), and the donor chamber was filled with 180 mL diluted test compound. The PAMPA sandwich was assembled, placed on the Gut-box and stirred for 30 min. Aqueous Boundary Layer was set to 40 mm for stirring. The UV spectrum (250–500 nm) of the donor and the acceptor were read. The permeability coefficient was calculated using PAMPA evolution 96 command software (pION Inc., Woburn, MA) based on the AUC of the reference plate, the donor plate and the acceptor plate. All compounds were tested in triplicates.

#### 4.5. Chemi-informatic analyses

The analysis of structure activity relationships was performed in Osiris DataWarrior V 3.12.1 (Actelion Pharmaceuticals Ltd.) freely available at (<http://www.openmolecules.org/>).<sup>34,35</sup> Activity Cliff Analysis was performed with similarity criterion as Skeleton-Spheres descriptor, which considers stereochemistry, counts duplicate fragments and encodes hetero-atom depleted skeletons as the most accurate descriptor for calculating similarities of chemical graphs. The similarity limit threshold was set to 80%.

Physiochemical properties descriptors and Quantitative Estimate of Drug-likeness (QED) were predicted with Discovery Studio (Accelrys Software Inc., V4.0) using CHARMM force field simulations on all structures (mol files in supplementary information). An energy minimization cascade was performed using an energy tolerance of 0.001 kcal/mol. ADMET descriptors were predicted using the small-molecule protocols for intestinal absorption, aqueous solubility, blood–brain barrier penetration, plasma protein binding, cytochrome P450 2D6 inhibition, and hepatotoxicity. The QED was determined for each structure using small-molecule protocols predicting molecular weight, lipophilicity, hydrogen bond donors, hydrogen bond acceptors, rotatable bonds aromatic rings, violations of Lipinski's rules and the quantitative estimate of drug-likeness value.

#### 4.6. Statistical analyses

Unless otherwise stated, all data are of at least three independent biological experiments ( $n \geq 3$ ), each performed in triplicate. Statistical analysis was performed using either paired or unpaired Student *t*-tests to indicate statistical significance. Data were analyzed using GraphPad Prism 5.0.

#### Acknowledgements

We thank Kathryn Wicht for assistance with the  $\beta$ -hematin inhibition assays at the University of Cape Town; Colin Dubick, Ethan Marrow, Youxuan Li for assistance with chemical synthesis at University of South Carolina and Gloria Holbrook and Fangyi Zhu for assistance with physicochemical properties at St Judes. This work was supported by the South African National Research Foundation (FA2007050300003 & UID: 84627), the University of Pretoria and the South African Medical Research Council Strategic Health Initiatives Partnerships with the Medicines for Malaria Venture for funding. Any opinion, findings and conclusion expressed in this paper are those of the author(s) and therefore the NRF does not accept any liability in regard hereto.

## Supplementary data

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.bmc.2015.01.036>. These data include MOL files and InChIKeys of the most important compounds described in this article.

## References and notes

- Meister, S.; Plouffe, D. M.; Kuhen, K. L.; Bonamy, G. M.; Wu, T.; Barnes, S. W.; Bopp, S. E.; Borboa, R.; Bright, A. T.; Che, J.; Cohen, S.; Dharia, N. V.; Gagaring, K.; Gettayacamin, M.; Gordon, P.; Groessl, T.; Kato, N.; Lee, M. C.; McNamara, C. W.; Fidock, D. A.; Nagle, A.; Nam, T. G.; Richmond, W.; Roland, J.; Rottmann, M.; Zhou, B.; Froissard, P.; Glynn, R. J.; Mazier, D.; Sattabongkot, J.; Schultz, P. G.; Tuntland, T.; Walker, J. R.; Zhou, Y.; Chatterjee, A.; Diagona, T. T.; Winzeler, E. A. *Science* **2011**, *334*, 1372.
- Rottmann, M.; McNamara, C.; Yeung, B. K.; Lee, M. C.; Zou, B.; Russell, B.; Seitz, P.; Plouffe, D. M.; Dharia, N. V.; Tan, J.; Cohen, S. B.; Spencer, K. R.; Gonzalez-Paez, G. E.; Lakshminarayana, S. B.; Goh, A.; Suwanarusk, R.; Jegla, T.; Schmitt, E. K.; Beck, H. P.; Brun, R.; Nosten, F.; Renia, L.; Dartois, V.; Keller, T. H.; Fidock, D. A.; Winzeler, E. A.; Diagona, T. T. *Science* **2010**, *329*, 1175.
- Charman, S. A.; Arbe-Barnes, S.; Bathurst, I. C.; Brun, R.; Campbell, M.; Charman, W. N.; Chiu, F. C.; Chollet, J.; Craft, J. C.; Creek, D. J.; Dong, Y.; Matile, H.; Maurer, M.; Morizzi, J.; Nguyen, T.; Papastogiannidis, P.; Scheurer, C.; Shackleford, D. M.; Sriraghavan, K.; Stingelin, L.; Tang, Y.; Urwyler, H.; Wang, X.; White, K. L.; Wittlin, S.; Zhou, L.; Vennerstrom, J. L. *Proc. Natl. Acad. Sci. U.S.A.* **2011**, *108*, 4400.
- Coteron, J. M.; Marco, M.; Esquivias, J.; Deng, X.; White, K. L.; White, J.; Koltun, M.; El Mazouni, F.; Kokkonda, S.; Katneni, K.; Bhamidipati, R.; Shackleford, D. M.; Angulo-Barturen, I.; Ferrer, S. B.; Jimenez-Diaz, M. B.; Gamo, F. J.; Goldsmith, E. J.; Charman, W. N.; Bathurst, I.; Floyd, D.; Matthews, D.; Burrows, J. N.; Rathod, P. K.; Charman, S. A.; Phillips, M. A. *J. Med. Chem.* **2011**, *54*, 5540.
- Younis, Y.; Douelle, F.; Feng, T. S.; Cabrera, D. G.; Manach, C. L.; Nchinda, A. T.; Duffy, S.; White, K. L.; Shackleford, D. M.; Morizzi, J. *J. Med. Chem.* **2012**, *55*, 3479.
- Wallace, H. M.; Fraser, A. V.; Hughes, A. *Biochem. J.* **2003**, *15*, 1.
- Wallace, H. M.; Fraser, A. V. *Biochem. Soc. Trans.* **2003**, *31*, 393.
- Zou, Y.; Wu, Z.; Sirisoma, N.; Woster, P. M.; Casero, R. A.; Weiss, L. M.; Rattendi, D.; Lane, S.; Bacchi, C. J. *Bioorg. Med. Chem. Lett.* **2001**, *11*, 1613.
- Seiler, N.; Atanassov, C. L.; Raul, F. *Int. J. Oncol.* **1998**, *13*, 993.
- Fraser, A. V.; Woster, P. M.; Wallace, H. M. *Biochem. J.* **2002**, *367*, 307.
- Casero, R. A.; Marton, L. J. *Nat. Rev. Drug Disc.* **2007**, *6*, 373.
- Bitonti, A.; Dumont, J.; Bush, T.; Edwards, M.; Stemerick, D.; McCann, P.; Sjoerdsma, A. *Proc. Natl. Acad. Sci. U.S.A.* **1989**, *86*, 651.
- Woster, P. M. *Ann. Rep. Med. Chem.* **2003**, *5*, 203.
- Hanson, W.; Baumann, R. J.; McCann, P. P.; Sjoerdsma, A.; Bitonti, A. *J. Antimicrob. Agents Chemother.* **1990**, *34*, 722.
- Baohbedaso, M.; Bellevue, F. H.; Wu, R.; Woster, P. M.; Casero, R. A., Jr.; Rattendi, D.; Lane, S.; Bacchi, C. J. *Bioorg. Med. Chem. Lett.* **1996**, *6*, 2765.
- Dumont, J.; Bitonti, A. J.; Bush, T. L.; Edwards, M. L.; Stemerick, D. M.; McCann, P. P.; Sjoerdsma, A. *Proc. Natl. Acad. Sci. U.S.A.* **1989**, *86*, 651.
- William, M.; Birkholtz, L. M.; Niemand, J.; Louw, A. I.; Persson, L.; Heby, O. *Biochem. J.* **2011**, *438*, 229.
- Verlinden, B. K.; Niemand, J.; Snyman, J.; Sharma, S. K.; Beattie, R. J.; Woster, P. M. a.; Birkholtz, L. J. *Med. Chem.* **2011**, *54*, 1.
- Sharma, S. K.; Wu, Y.; Steinbergs, N.; Crowley, M. L.; Hanson, A. S.; Casero, R. A. a.; Woster, P. M. *J. Med. Chem.* **2010**, *53*, 5197.
- Dominguez, J. N.; Leon, C.; Rodrigues, J.; De Dominguez, G. N.; Gut, J. a.; Rosenthal, P. J. *J. Med. Chem.* **2005**, *48*, 3654.
- Mei, Z.; Wang, L.; Lu, W.; Pang, C.; Maeda, T.; Peng, W.; Kaiser, M.; Sayed, I. E. a.; Inokuchi, T. *J. Med. Chem.* **2013**, *56*, 1431.
- Egan, T. J.; Koch, K. R.; Swan, P. L.; Clarkson, C.; Van Schalkwyk, D. A. a.; Smith, P. J. *J. Med. Chem.* **2004**, *47*, 2926.
- Carter, M. D.; Phelan, V. V.; Sandlin, R. D.; Bachmann, B. O.; Wright, D. W. *Comb. Chem. HTS* **2010**, *13*, 285.
- Liew, L. P.; Kaiser, M.; Copp, B. R. *Bioorg. Med. Chem. Lett.* **2013**, *23*, 452.
- Liew, L. P.; Pearce, A. N.; Kaiser, M.; Copp, B. R. *Eur. J. Med. Chem.* **2013**, *69*, 22.
- Burrows, J. N.; van Huijsduijnen, R. H.; Mohrle, J. J.; Oeuvray, C.; Wells, T. N. *Malar. J.* **2013**, *12*, 187.
- Assaraf, Y. G.; Abu-Elheiga, L.; Spira, D. T.; Desser, H. a.; Bachrach, U. *Biochem. J.* **1987**, *242*, 221.
- Le Manach, C.; Scheurer, C.; Sax, S.; Schleiferbock, S.; Cabrera, D. G.; Younis, Y.; Paquet, T.; Street, L.; Smith, P.; Ding, X. C.; Waterson, D.; Witty, M. J.; Leroy, D.; Chibale, K.; Wittlin, S. *Malar. J.* **2013**, *12*, 424.
- Leroy, D.; Campo, B.; Ding, X. C.; Burrows, J. N.; Cherbuin, S. *Trends Parasitol.* **2014**, *30*, 478.
- Adjalley, S. H.; Johnston, G. L.; Li, T.; Eastman, R. T.; Ekland, E. H.; Eappen, A. G.; Richman, A.; Sim, B. K.; Lee, M. C.; Hoffman, S. L.; Fidock, D. A. *Proc. Natl. Acad. Sci. U.S.A.* **2011**, *108*, E1214.
- Sun, W.; Tanaka, T. Q.; Magle, C. T.; Huang, W.; Southall, N.; Huang, R.; Dehdashti, S. J.; McKew, J. C.; Williamson, K. C.; Zheng, W. *Sci. Rep.* **2014**, *4*, 3743.
- Duffy, S.; Avery, V. M. *Malar. J.* **2013**, *12*, 408.
- Birkholtz, L. *Encyclopedia of Malaria. In Polyamine Metabolism in Plasmodia; Ginsburg, H., Ed.; Springer, 2013. Chapter 2.*
- Guha, R.; Van Drie, J. H. *J. Chem. Inf. Model.* **2008**, *48*, 1716.
- Guha, R.; Van Drie, J. H. *J. Chem. Inf. Model.* **2008**, *48*, 646.
- Edwards, M. L.; Stemerick, D. M.; Bitonti, A. J.; Dumont, J. A.; McCann, P. P.; Bey, P.; Sjoerdsma, A. *J. Med. Chem.* **1991**, *34*, 569.
- Bergeron, R.; Hawthorne, T.; Vinson, J.; Beck, D. J.; Ingenu, M. *Cancer Res.* **1989**, *1*, 2959.
- Bergeron, R. J.; McManis, J. S.; Weimar, W. R.; Schreier, K. M.; Gao, F.; Wu, Q.; Ortiz-Ocasio, J.; Luchetta, G. R.; Porter, C.; Vinson, J. R. *J. Med. Chem.* **1995**, *38*, 2278.
- Melchiorre, C.; Bolognesi, M. L.; Minarini, A.; Rosini, M. a.; Tumiatti, V. *J. Med. Chem.* **2010**, *53*, 5906.
- Lopez, C.; Bi, X.; Bacchi, C. J.; Rattendi, D.; Woster, P. M. *Bioorg. Med. Chem. Lett.* **2006**, *16*, 3229.
- Angyal, W. W.; Warburton, W. *J. Chem. Soc.* **1951**, 1951, 2492.
- Rodima, T.; Kaljurand, I.; Leito, I.; Koppel, I. A.; Schwesinger, R. *J. Org. Chem.* **2000**, *65*, 6202.
- Wallace, A. V.; Wallace, H. M.; Hughes, A. *Biochem. J.* **2003**, *376*, 1.
- Bi, X.; Lopez, C.; Bacchi, C. J.; Rattendi, D.; Woster, P. M. *Bioorg. Med. Chem. Lett.* **2006**, *16*, 3229.
- Trager, W. A.; Jensen, J. B. *Science* **1976**, *193*, 673.
- Lambros, C.; Vanderberg, J. P. *J. Parasitol.* **1979**, *65*, 418.
- Smilkstein, M.; Sriwilaijaroen, N.; Kelly, J.; Wilairat, P.; Riscoe, M. *Antimicrob. Agents Chemother.* **2004**, *48*, 1803.
- Malmquist, N. A.; Moss, T. A.; Mecheri, S.; Scherf, A. a.; Fuchter, M. J. *Proc. Natl. Acad. Sci. U.S.A.* **2012**, *1*.
- Ncokazi, K. K.; Egan, T. J. *Anal. Biochem.* **2005**, *338*, 306.
- Lucantoni, L.; Duffy, S.; Adjalley, S. H.; Fidock, D. A.; Avery, V. M. *Antimicrob. Agents Chemother.* **2013**, *57*, 6050.